‘Recovery Trial’ finds anti-arthritis drug reduces severe COVID-19 mortality
The trial found that Baricitinib reduces the mortality of hospitalized patients by 13%. Baricitinib inhibits the enzymes of a specific family of enzyme called the Janus Kinase (JAK) family
COVID-19 treatment: SOLIDARITY trial is restarting with 3 drugs this time
The drug candidates for repurposing are imatinib, a cancer drug; infliximab, an antibody; and artesunate, an anti-malarial drug. The tests seek to explore possible drugs that can be repurposed to treat severely affected COVID-19 patients
Break Gilead’s patent since US has bought all stock of Remdesivir
Trump is trying to improve his waning electoral chances by reserving all of Gilead’s stock of Remdesivir to cover up his disastrous handling of the Covid-19 epidemic so far
COVID-19: Dexamethasone provides some hope for severely ill
In a trial, Dexamethasone, an inexpensive and widely used corticosteroid, reduced deaths by one-third in ventilated patients and by one-fifth in patients receiving oxygen support
Covid-19 and Dexamethasone: Some hope for serious patients
A randomised and controlled clinical study conducted in the UK has found that the readily available steroid drug, Dexamethasone, could be a game changer in treating critically ill COVID-19 patients.
- Accusations and attacks mark Mexico’s second presidential debate
- Measles in Chicago sparks misdirected blame against migrants
- Palestinian students and academics express solidarity with university encampments across the globe
- “We’ve always been here!”: Indigenous peoples release final declaration of Terra Livre Camp 2024
- Colombia to make HIV treatment more accessible through compulsory licensing
